click company/industri name report summari
price estim chang
tibsovo launch get boost idhifa commun uptak key buy pt
still great time invest stellar highlight biz momentum buy target
note road fda chang heart breath new life stori buy pt
usher much sober outlook buy pt
top line momentum strong oper leverag buy pt
remain sidelin face increas us competit hold pt
laboratori corpor america hold lh-nyse us
beat commentari mix lower estim share loss pt
realli lot like much fret buy pt
solid outlook modest hit hold pt
nxp deal expir sever long-term growth driver reiter buy pt
biomed devic servic
takeaway yesterday medcac panel neutral posit tavr player ew
favor setup phase dri eye data buy pt
posit phase data lucenti long-term implant interest safeti key hold pt
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object view
design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author fca report
european issuer non-independ research market commun market abus regul fca conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx recommend
opinion express research report accur reflect analyst person independ object view design invest
import inform pleas see import disclosur begin page document
look fine eye new ceo commentari execut buy
pension sell stock increas may make bull market stronger
casual dine trim compstore forecast juli commod price improv sequenti
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object view
design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author fca report
european issuer non-independ research market commun market abus regul fca conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx recommend
opinion express research report accur reflect analyst person independ object view design invest
tibsovo launch get boost idhifa
tibsovo uptak robust idhifa commun clinic key
current physician experi idhifa relapsed/refractori aml
give tibsovo steeper launch trajectori base better familiar mechan
action vs tradit chemotherapi importantli believ idhifa launch
suffer doctor use drug myeloabl may
immedi lower blast count patient addit agio claim
relapsed/refractori aml patient receiv idh test look detail
commun set encouragingli recent public connect mds/aml
diseas registri indic newli diagnos aml patient undergo genet test
academ set vs commun set
month durat idhifa encourag
patient current receiv idhifa month averag consist
median suggest similar eventu median durat tibsovo relapsed/
refractori aml could expect shorten durat initi physician may
discontinu use reason progress becom familiar
front-lin hold larg opportun tibsovo
front-lin aml opportun import tibsovo revenu specif
mainten period test phase assum phase
agil studi combin vidaza /- tibsovo show overal surviv benefit
aml patient encourag continu usag mainten assum
mainten benefit also soon howev look detail discontinu
due progress mainten although minim patient
reach mainten like toler drug
maintain buy rate pt moder tibsovo
revenu somewhat drug launch late summer patient may
holiday due slower expect uptak idhifa us tibsovo
estim vs previous declin
declin declin
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
aerospac defens
ba report core ep includ litig charg
charg ahead estim consensu total sale growth
quarter quarter saw good execut backlog growth
gener increment confid commerci oe cycl believ
tanker charg lack increas ep guidanc headwind
stock ba rais revenu bca margin guidanc maintain hold
rate price target
recogn total after-tax higher cost tanker
bca bd quarter program schedul
final forc first deliveri octob initi april
ba incur addit cost incorpor chang exist aircraft
increment flight test engin charg surpris
believ neg impact sentiment stock rais concern
higher cash usag tanker potenti develop program ba
maintain full year guidanc even addit charg
bca margin posit quarter come
charg estim block extens key driver
compani also highlight mix especi supplier price step-down
execut compani guid slight step-up sequenti cost
well relat invest full year bca margin
roughli in-lin upward revis guidanc part result
manag re-confirm final decis nma launch
stick ei continu believ compani launch program
key step valid life cycl opportun servic well digit
design effort ba develop moreov nma logic step fsa
repres much signific market opportun extend
block aircraft remain track rate program
defer reduct per aircraft expect
deliv mix signific tailwind head
compani reiterate push higher rate suppli chain concern
continu gate factor view howev continu believ boe
eventu push like
maintain hold rate price target sentiment
commerci cycl improv come farnborough order
activ far year impress moreov ba seem track mid-
teen margin bca busi would posit continu see bd
margin lag howev near-term continu see trade macro concern
limit upsid longer term believ compani increas
invest support nma sentiment upsid limit
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
still great time invest stellar
highlight biz momentum buy target
bottom line repres anoth stellar growth quarter firm
perform across firm busi strong recent momentum neuro
ep endo uro continu quarter notabl
manag slightli increas guidanc rang rais structur heart
expect vs previous project research still
impli conserv driven strong momentum firm watchman
sequenti step-up well tavr symeti run-rat approach
estim
recommend investor continu add posit increas
target continu favor believ firm
long-term strategi deliv organ growth via technolog differenti global
breadth target med-tech market believ offer stronger underli growth
prospect peer compar latter cumul med-tech franchis
bsc also like quantiti qualiti inher flurri
recent tuck-in acquisit nxthera apama cryterion etc coupl strong
opex manag prowess shown posit firm deliv
revenu pro forma ep growth acceler level
estim sum still think great time invest reiter buy
structur heart momentum across firm watchman tavr busi
continu franchis experienc strong sequenti growth
amid posit adopt trend heel perform manag
increas full-year expect structur heart busi vs
previous albeit research suggest may still prove conserv
benchmark leav room upsid guidanc view
watchman util continu increas support signific sequenti ramp
sale util reorder rate new account addit track posit
expect busi continu benefit near term lotuss delay
entri us bsx us structur heart team interim focus entir
watchman least commenc acur trial later year
think addit feet street drive watchman adopt util could
key driver upsid manag guidanc
tavr side acur revenu continu track ahead initi intern
expect ramp sequenti gain increment share ou acur
sale total europ sale today
still small player tavr market ultim think much bigger
forc tavr long term base current trend busi manag
anticip symeti provid posit impact bsx report sale
continu pg
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
note road fda chang heart breath
new life stori buy pt
come away recent investor meet correvio ceo hunter cfo
justin renz impress progress compani abl make advanc
brinavess fda seemingli blue extrem compel
stori built acut care franchis ex-north american market strong growth
expect core anti-infect product potenti approv trevyent
meaning option associ brinavess asset us market given recent
progress fda correvio one favorit name specialti pharma
reiter buy rate corv share increas price target
us progress brinavess repres meaning opportun npv analysi
indic much spectrum safeti studi
abl convinc fda path forward brinavess essenti
left dead time last year pleasantli surpris encourag
agenc quick revers willing engag correvio approv
us launch right set small-town rural er littl specialist
support see brinavess revenu high million peak
address first-tim cardiovers conduct pharmacolog
addit share shift dc cardiovers would addit estim
uthr/steadym deal give correvio much stronger partner easier
competit posit trevyent announc acquisit
steadym like close soon see deal leav correvio much stronger
partner trevyent like posit follow-on remodulin
encourag cooper instead competit treprostinil space
recent develop give correvio plenti strateg flexibl brinavess
win us approv see three potenti option correvio think self-launch
would challeng compani either acquisition/licens larg pharma
partner seek build cardiovascular franchis potenti acquisit
mid-cap cardio-focus compani like could benefit correvio european
presenc extens distributor relationship like think correvio may
seek creativ transact one-product us compani especi anti-infect
critic care could leverag commerci infrastructur side
atlant combin organ regardless see correvio continu seek
hospital-bas product european bag broader distribut relationship
reiter buy rate rais pt given correvio solid strateg flexibl
solid opportun ex-brinavess reiter buy rate corv share
time ad bit risk-adjust us brinavess opportun valuat
model rais dcf- npv-driven pt
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
usher much sober outlook buy pt
brought major surpris facebook revenu growth significantli impact
fx shift usag toward lower-monet stori potenti gdpr-relat
headwind least equal import conclud long-term plan process
higher cost relat safeti secur continu data center expans
lesser extent video content view revenu slowdown temporari issu
fx headwind may persist quarter structur engag
advertis appear happi margin outlook discourag realist less
overli cautiou polit either way crank model lower
multipl still get us reason return after-hour move
bullish oper incom ep beat consensu
bearish user revenu miss consensu revenu guidanc
consensu lt margin guidanc set vs consensu
user revenu growth deceler dau mau miss consensu
gdpr caus sequenti declin european user asia
row growth deceler expect also currenc tailwind
fxn growth rel report expect flip
headwind relat manag guid growth continu
deceler meaning high single-digit sequenti deceler
impli exit driver slower revenu growth roughli rank
currenc headwind promot lower monet ad stori data
privaci impact gdpr new privaci option
instagram put take instagram still larg opportun
contribut grow rapidli reach user june recent
develop suggest enough save back-half deceler firstli
manag note ad load instagram feed compar
facebook feed secondli impress growth acceler
continu messag slowdown driven partli ad instagram
revenu growth guidanc also partial due promot lower-monet
stori ad perhap best known instagram platform
chang margin structur addit hold expens growth guidanc
manag guid long-term steady-st oper margin
contract level next year differ prior
consensu major area invest anticip
order safeti secur innov ad product capital-expenditure
flow incom statement cog content cost relat video
growth cog reflect guidanc oper margin
lower estim notic reflect slower revenu growth lower
margin pt goe base ep
time write stock hour trade
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
top line momentum strong oper leverag buy
pt
report strong result record organ new diner improv order
frequenc expand take rate revenu adj ebitda ahead
estim increas full year guidanc impli strength
like continu invest deliveri chain partnership tier
 market expans multipl strateg acquisit pay dividend
acceler on-line transit food takeout deliveri market
announc acquisit levelup meaning enhanc technolog
capabl allow form deeper relationship restaur brand
consum outlin initi note go mass market see strong
structur tailwind continu slowli steadili grow billion
address market on-line penetr still valuat
premium level offer uniqu combin growth strong
profit expect stock strength continu
strong quarter across board net diner add brought end activ
diner slightli ahead estim consensu diner growth
particularli strong june continu momentum juli take rate
highest compani histori benefit diner order
higher-pay restaur on-going mix shift toward deliveri order
expand core take rate restaur pay higher exposur
show strong oper leverag revenu beat drive adj ebitda
levelup acquisit bring signific opportun announc
propos acquisit levelup restaur technolog compani provid
custom order payment loyalti platform levelup current
work approxim differ custom process in-person pickup
order daili gener food sale per year unlik prior deal
orderup acquisit intend increas scale enhanc
depth levelup product suit differ exist offer allow
compani offer restaur alreadi work complet set
transact manag tool also opportun compani convert
meaning portion levelup custom pickup order grubhub-fulfil deliveri
increas full year guidanc suggest oper strength like continu
guidanc revenu ebitda came
ahead consensu respect full-year revenu guidanc revis upward
full year ebitda increas
updat guidanc incorpor announc levelup acquisit
busi gener annual run-rat revenu grow per year
oper modest ebitda burn
rais estim price target base
higher ebitda estim
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
remain sidelin face increas us
competit hold pt
reiter hold rate follow last night beat rais
intern strong gross margin buoy japan perform
us y/i lag full year growth rate necessari achiev revenu guidanc
continu view increas competit especi us concern chose
remain sidelin clearer pictur new product roadmap emerg
part base upward revis estim guidanc rais price target
report result revenu ep revenu
compar cg consensu estim quarter
respect ep significantli beat expect cg consensu
higher anticip gross margin delay market expens
gross margin second quarter last year higher
margin japan cog improv full year gross margin expect
high end previous provid rang meanwhil compani
push market expens second third quarter
manag highlight compani remain track previous
discuss second half product launch first soft launch higher
end product lower price point next week compani remain
commit target full year revenu to-be-releas
manag expect full year revenu
low end rang meanwhil oper incom
expect full year ep expect
within guidanc manag continu expect double-digit y/i revenu growth
sequenti quarterli growth quarter year profit
expect lowest moder higher overal opex expect
approxim revenu
revis estim rais price target
revenu reiter
ep reiter
price target rais price target base net cash price-to-earnings
estim
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
laboratori corpor america hold
diagnost tool
beat commentari mix lower
estim share loss pt
lh deliv beat narrow guid typic good enough
keep stock flat least street need lower outlook lh expect
share loss contract think today pullback attribut
realiti estim high given situat slight miss
covanc concern lh achiev slightli rais covanc guid
brief secur breach occur earli juli expect volum
lh affirm revenue impact higher denial test vitamin
reduct hcvg test said big pictur intact reiter
buy trim pt ep lh trade ntm ep
unh/aet surprisingli lh acknowledg expect see neg impact
revenu profit result lose exclus
partial off-set volum gain aet said lh acknowledg
pleas in-network price contract aet next year
us suggest lh lose volum make revenue loss
higher price expect share shift gradual recal lh today
deriv lab rev
result adj ep beat street line
rev y/i beat driven
beat dx busi partial off-set miss vs estim
lh dx rev beat /street volum
rose strong beat organ volum help
beat ad point growth rev/req
level miss pama cut strong volum
lower price test lh lh acknowledg revenu
volum headwind relat limit coverag polici vitamin
covanc rev miss street
fx ad growth lh indic organ growth covanc
hover mid-to-high singl digit quantifi specif organ growth
growth came chiltern acquisit lh indic
earli develop segment strong clinic central lab work shift
covanc backlog lh expect
convert revenue net order came
net book-to-bil
guid lh tighten revenue guid y/i
reflect divestitur food solut busi off-set
increas covanc guid lh tighten adj ep guid
lh expect rev diagnost
reflect divestitur food solut
due chiltern higher investig fee pass-through revenu
covanc note chiltern anniversari
model chang model comment next page
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
realli lot like much fret buy pt
momentum continu confer call question reason
felt like us tri get edg bowl ball easi
three hole finger basic firm roll market
mani busi softwar stock reach silli valuat run short-
long-term valuat methodolog firm still get green light prospect
return investor need rememb year roughli half softwar
deploy self-written code versu pre-packag applic firm like
sap ca etc doubt compani scheme replac core
system record stack highli confid
run rampant half market compris legaci system process
quarter alter six-year-old assert special compani
like scale becom signific platform buy
bullish item report strong quarter upsid across board
pretti much everi metric track compani sign transact
net new acv bring total count custom y-o-i number
custom acv doubl y-o-i although less signific
indic use compani saw bounc back sign ad
quarter vs emerg product repres new acv
although slightli sequenti sinc establish
product saw strong quarter itom particular see deal acv
includ largest ever
bearish item littl pick fundament perspect
continu deliv quarter quarter surfac report result
guidanc subscript revenu bill impact recent swing
fx result impact metric expect
metric lower respect
number solid quarter report revenu y-o-i
constant currenc non-gaap oper margin bp y-o-i
ep respect bp ahead
estim subscript revenu revenu mix gross margin north
subscript bill came y-o-i
estim adjust came quarter ahead estim
outlook fx nois gener expect revenu expect
larg reiter year currenc adjust revenu guidanc increas
high end rang last quarter reiter full-year
expect gross oper margin given out-performance first
half year track record suspect potenti upsid rel
expect year play
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
solid outlook modest hit hold pt
paypal report solid result compani exceed revenu ep estim
although share fell after-hour trade owe revenu guidanc came
expect despit initi reaction paypal earn manag
reiter upbeat outlook back yet anoth quarter y/i tpv
growth revenu growth furthermor paypal demonstr proactiv
approach util free cash flow announc four acquisit quarter
well new stock repurchas program follow current
repurchas author remain avail end
said fairli premium multipl rel growth clear line sight
growth inflect continu find share fairli valu
bullish revenu ep beat consensu slightli rais revenu ep
bearish revenu guidanc consensu
tpv revenu growth remain impress tpv grew y/i fx-neutral
vs revenu grew y/i vs much like
previou quarter paypal highlight custom choic initi grow
partnership strategi growth lever continu strong perform meanwhil
manag highlight strong engag mobil platform payment
volum increas quarter repres
growth y/i record overal tpv
strateg acquisit stock repurchas signal manag strategi
shed light paypal strateg prioriti go forward announc
four acquisit quarter alongsid acquisit izettl
acquisit jetlor past may paypal also announc acquisit
hyperwallet simil last month respect
addit paypal also state close consum credit receiv
transact synchroni result paypal receiv total consider
lastli paypal board author new stock repurchas program
becom effect follow complet current repurchas
guidanc manag revenu guidanc came
consensu ep guidanc in-lin estim
upcom quarter howev paypal slightli rais revenu ep
guidanc
respect revis estim reflect impact complet
announc acquisit expect close end year
modestli tweak estim price target goe base
slightli lower non-gaap ep estim
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
nxp deal expir sever long-term
growth driver reiter buy pt
invest recommend midnight et juli termin
deal purchas nxp intend pay fee nxp increas share
repurchas program target complet vast major end
believ end uncertainti buy nxp posit share
anticip strong earn growth next sever year due increas
share repurchas program likelihood settl huawei next
year long-term drive market share gain adjac market growth
opportun report result pro-forma ep well
ahead estim primarili driven partial payment huawei
part on-going licens negoti also due strong snapdragon
sale chines oem qct post stronger sale margin estim
remain encourag manag reiter target non-gaap ep
exclud settl licens disput view partial payment huawei
posit step toward long-term deal lead smartphon oem despit
licens disput huawei inabl close nxp believ
attract invest opportun long-term investor
believ eventu settl disput two lead smartphon
oem earn ramp help buy-back beyond
enabl gain market share anticip manag
updat plan share repurchas plan come week
increas estim assum repurchas roughli share
pleas see scenario analysi page updat price target
increas base assumpt share buy-back settl licens
disput huawei
buy-back drive earn growth increas non-
gaap ep estim primarili due anticip share
repurchas note estim exclud settl licens deal
huawei slightli target due part
elev legal expens estim given uncertain time settl
anticip could institut dutch auction type process
larg buy-back potenti conserv model larg buy-back
assum happen throughout cours shown figur page
believ achiev non-gaap ep appl
settl half pay disput huawei also settl
believ consist low-end qualcomm target
licens disput get resolv
increas estim due partial payment huawei strong qct trend
increas non-gaap ep estim note
increas non-gaap ep estim assum
execut buy-back qct trend remain strong lead android oem
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
price close busi jul
takeaway yesterday medcac panel neutral
posit tavr player ew
bottom line yesterday medcac panel fairli benign view panel
ultim ramif like neutral posit tavr industri overal
chief concern head meet center potenti increas volum
requir begin maintain tavr center potenti limit widespread patient
access technolog
tavr volum threshold issu initi brought februari
public multi-societi aats/acc/scai/st consensu statement around
oper institut requir tavr suggest increas current
tavr volum threshold center maintain tavr program warrant
current stand cmss ncd establish certain volum requir hospit
heart team member begin maintain tavr program focu
panel highlight balanc outcom patient access use volume-
base measur panel discuss specif volum requir come
meet definit volum set vote matter
maintain tavr program clear us establish protocol
limit number tavr center align panel interest provid
adequ access tavr patient view panelist support idea
establish threshold structur heart diseas procedur volum
volum requir come expens tavr access
consid yesterday discuss takeaway reassess current
market stand today tavr center establish us collect
perform procedur annual basi approxim penetr
nearli potenti address patient current ncd estim us
penetr reach upsid estim ultim
becom less restrict tavr center requir base heard
panel yesterday think unlik ultim make tavr center
requir stricter higher likelihood new guidelin either stay
becom lenient think takeaway tavr player name edward ew buy
 buy neutral posit
certain requir center becom approv tavr center among
requir center must possess on-sit heart valv surgeri team cardiac cath
lab hybrid or/cath lab equip radiograph imag post-procedur
icu open heart personnel experi patient must undergo examin
two independ cardiac surgeon order consid tavr procedur
continu pg
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
favor setup phase dri eye data buy pt
trend across multipl endpoints/ind phase dri eye constitut success
reproxalap may show consist improv trend across multipl endpoint
phase dri eye result success view importantli previous approv
drug includ xiidra restasi shown repeat improv across two
endpoint fda comment xiidra indic agenc open trial data show
one symptom improv replic two trial one sign improv replic
two trial previou data show reproxalap confer benefit across multipl
metric symptom assess dri sand score ocular discomfort score overal
four-symptom score schirmer tear volum test tear osmolar lissamin green
phase power statist signific
reiter point current phase trial power statist
signific studi need show statist signific
differ reproxalap vs vehicl constitut success view
exact perform vehicl control arm known
test trial design identifi optim dose
trial may requir patient power vs
current design would extrem costli clinical-stag compani
unsound financi strategi furthermor would like remind investor
vehicl control phase dri eye studi rel aqueou
minim placebo respons boost efficaci differ reproxalap vs
scenario analysi trial outcom
scenario analysi indic street current heavili price worst-cas
scenario reproxalap dri eye phase would show low
activ reproxalap rel vehicl given trial design power
statist signific vehicl show consider activ
given aqueou properti believ rel under-valued assess three
possibl scenario scenario analysi reproxalap show statist signific
superior one signal one symptom reproxalap trend toward improv
multipl sign symptom reproxalap show low activ
maintain buy rate price target base
continu expect posit phase data dri eye posit phase data
allerg conjunct also posit phase data sl
anterior noninfecti uveiti
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
posit phase data lucenti long-term implant
interest safeti key hold pt
genentech report top-lin phase ladder trial port deliveri system
phase ladder trial show portabl deliveri system pd
ml lucenti achiev similar bcva gain reduct central retina thick
lucenti inject patient neovascular could lead
increas competit regn eylea importantli major pd patient
went month implant first refil six-month dose
pd could significantli lower treatment burden patient mani patient
may feel uncomfort long-term implant eye wait data
updat assess overal efficaci system better understand overal valu
proposit potenti impact eylea genentech expect initi phase
trial later
safeti major point focu
interest safeti signal regard ocular pressur chang
lead discontinu lucenti given via pd major
effect uptak await safeti detail phase phase studi show
sae patient associ devic placement one occurr
endophthalm success treat patient gain three letter visual
acuiti vs baselin sae result persist vitreou hemorrhag
one patient gain four letter baselin month second hand
motion visual acuiti month addit sae occur involv traumat
cataract relat implant procedur howev patient underw
phacoemulsif iol implant result gain letter
econom physician may neg impact implant use
implant devic would reduc number inject visit patient
reduc payment physician potenti impact uptak howev given
devic refil use custom needl physician might abl achiev
similar econom depend price contract strategi implement
maintain hold pt base continu concern lack eylea guidanc
potenti competit roch dme novarti brolucizumab
new pd formul genentech wet believ dupix
like approv uncontrol persist asthma octob view
pediatr indic approv key impact inflect point compani
cemiplimab approv cscc highli like octob also continu
monitor develop frontlin nsclc trial high bar success
incumb therapi
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
look fine eye new ceo commentari
smith nephew report sale y/i slightli
our/street estim sale quarter support
underli strength emerg market off-set soft trauma aet
advanc wound manag ep came estim
one penni consensu high level view result
broadli posit snn appear continu take share global knee market
key focu investor given knee repres overal revenu mix
histor basi said expect near-term investor sentiment driven
commentari new ceo vision corpor strategi near-
term execut outlin notabl takeaway releas
publish full thought follow call
recon perform well led above-market growth strong ou knee
underli us/ou solid us hip underli us/ou
sport medicin joint repair perform ahead compani expect
led strong growth recent acquir regeneten implant rotat cuff repair
manag reiter expect underli revenu growth
bracket estim trade profit margin level vs
estim y/i
first look sale
total revenu our/street estim
global hip/kne sale compar estim
us knee y/i vs estim us hip vs
estim growth
trauma extrem sale y/i estim
sport medicin joint repair sale y/i estim
advanc wound manag sale larg line
estim
reiter underli revenu growth rang y/i vs
previou estim
reiter trade profit margin margin compar
previou estim y/i
reiter tax rate compar previou estim
confer call detail smith nephew host confer call today
et dial-in inform follow id
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
juli telig receiv fda approv hydrocortison cream repres
compani eighth anda approv year encourag telig topic
product approv flow concret step compani take address balanc
sheet howev continu wait valid telig new inject facil
think critic build sustain gener busi remain hold
rate tlgt share look updat compani earn call next
month point review estim valuat
product hydrocortison cream topic steroid use treat
inflamm skin caus allerg reaction eczema psoriasi
big market last month sale hydrocortison cream
concentr million broader hydrocortison cream
market million time frame
player player market includ rise brand
protcozone-hc sandoz taro teva gener crown salix
lannett also approv product
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
pension sell stock increas may make
pension reduc exposur equiti even though last
year bull market typic see strong price gain
pension sell may actual make equiti bull market stronger
pension shift money aggress credit product lead buyback
stock climb trend yesterday first time sinc march
consult drive pension invest alloc decis lower
expect equiti price gain come year new evid pension
act think reduc equiti exposur
behavior run counter trend final year bull market
modern financ era typic see strong stock price gain counter belief
credit-l equiti bull market like go persist anoth year
pension move may actual strengthen bull market money shift
aggress credit relat product gener buyback lbo merger
june column illustr consult commun lower equiti
market expect expens credit market expect week pension
 invest ran stori pension put thought action
reduc equiti exposur
stori titl asset owner fear volatil flock risk mitig strategi
detail numer pension increasingli util lower-volatil product
defens equiti product tri reduc equiti exposur
stori quot california public pension administr say much
equiti keep awak night
exactli wrong stanc pension take given focus
long term welcom bout volatil howev natur public
pension truste job often forc focu short term prefer credit
equiti shun volatil
illustr intens pension sell stock becom year decid
look bloomberg smart money index index compar action stock
price earli day close late-day money supposedli repres
smart money
trade contact know signific amount late-day money
pension money tri get close price chart next page show
intens late-day sell year
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
price close busi juli
casual dine trim compstore forecast juli
commod price improv sequenti
casual dine trim juli compstore forecast bp second week
juli casual dine restaur check suggest comp flattish
second consecut week view weather possibl effect given
heatwav condit across look week expect weather
could factor given near record temperatur texa part
countri histor excess hot condit seen slight drag
restaur industri comp particularli compani patio exposur
coverag list note hold del frisco
dfrg hold bj buy patio exposur
reflect slower expect comp juli lower compstore estim
month juli rang
commod updat food commod pressur measur spot market
price eas vs led deflat key beef chicken seafood produc
item commod track see commod heatmap pg
roughli year-over-year notabl except lime egg
across restaur univers expect better commod margin profil vs last
quarter albeit depend company-specif food contract cog like
posit theme earn season particularli compani beef
term greatest opportun deflat quarter expect benefit
steakhous categori like saw lower beef price particularli prime
cut provid favor dfrg also on-going suppli chain
initi anoth compani potenti outsiz favor chipotl mexican grill
 buy exposur avocado spot y/i
produc off-set somewhat higher lime skirt steak price
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
